Literature DB >> 20620143

Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection.

Eiji Takayama1, Takeshi Ono, Elena Carnero, Saori Umemoto, Yoko Yamaguchi, Atsuhiro Kanayama, Takemi Oguma, Yasuhiro Takashima, Takushi Tadakuma, Adolfo García-Sastre, Yasushi Miyahira.   

Abstract

We studied some aspects of the quantitative and qualitative features of heterologous recombinant (re) virus-vector-induced, antigen-specific CD8(+) T cells against Trypanosoma cruzi. We used three different, highly attenuated re-viruses, i.e., influenza virus, adenovirus and vaccinia virus, which all expressed a single, T. cruzi antigen-derived CD8(+) T-cell epitope. The use of two out of three vectors or the triple virus-vector vaccination regimen not only confirmed that the re-vaccinia virus, which was placed last in order for sequential immunisation, was an effective booster for the CD8(+) T-cell immunity in terms of the number of antigen-specific CD8(+) T cells, but also demonstrated that (i) the majority of cells exhibit the effector memory (T(EM)) phenotype, (ii) robustly secrete IFN-γ, (iii) express higher intensity of the CD122 molecule and (iv) present protective activity against T. cruzi infection. In contrast, placing the re-influenza virus last in sequential immunisation had a detrimental effect on the quantitative and qualitative features of CD8(+) T cells. The triple virus-vector vaccination was more effective at inducing a stronger CD8(+) T-cell immunity than using two re-viruses. The different quantitative and qualitative features of CD8(+) T cells induced by different immunisation regimens support the notion that the refinement of the best choice of multiple virus-vector combinations is indispensable for the induction of a maximum number of CD8(+) T cells of high quality.
Copyright © 2010 Australian Society for Parasitology Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20620143      PMCID: PMC2952726          DOI: 10.1016/j.ijpara.2010.05.011

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  57 in total

1.  Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen.

Authors:  O Bruña-Romero; G González-Aseguinolaza; J C Hafalla; M Tsuji; R S Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

Review 2.  Genetically modified viruses: vaccines by design.

Authors:  J R Stephenson
Journal:  Curr Pharm Biotechnol       Date:  2001-03       Impact factor: 2.837

Review 3.  A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells.

Authors:  F Zavala; M Rodrigues; D Rodriguez; J R Rodriguez; R S Nussenzweig; M Esteban
Journal:  Virology       Date:  2001-02-15       Impact factor: 3.616

4.  Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination.

Authors:  David Masopust; Sang-Jun Ha; Vaiva Vezys; Rafi Ahmed
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

Review 5.  Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses.

Authors:  Jonathan W Yewdell
Journal:  Immunity       Date:  2006-10       Impact factor: 31.745

6.  A DNA transfection system for generation of influenza A virus from eight plasmids.

Authors:  E Hoffmann; G Neumann; Y Kawaoka; G Hobom; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 7.  Functional signatures of protective antiviral T-cell immunity in human virus infections.

Authors:  Alexandre Harari; Valérie Dutoit; Cristina Cellerai; Pierre-Alexandre Bart; Renaud A Du Pasquier; Giuseppe Pantaleo
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

8.  Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus.

Authors:  J Oliveira-Ferreira; Y Miyahira; G T Layton; N Savage; M Esteban; D Rodriguez; J R Rodriguez; R S Nussenzweig; F Zavala; Y Myahira
Journal:  Vaccine       Date:  2000-03-06       Impact factor: 3.641

9.  Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy.

Authors:  Masaharu Katae; Yasushi Miyahira; Kazuyoshi Takeda; Hironori Matsuda; Hideo Yagita; Ko Okumura; Tsutomu Takeuchi; Tsuneo Kamiyama; Akihiko Ohwada; Yoshinosuke Fukuchi; Takashi Aoki
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

Review 10.  Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.

Authors:  Tomáš Hanke; Andrew J McMichael; Lucy Dorrell
Journal:  J Gen Virol       Date:  2007-01       Impact factor: 3.891

View more
  3 in total

Review 1.  Advances and challenges towards a vaccine against Chagas disease.

Authors:  Israel Quijano-Hernandez; Eric Dumonteil
Journal:  Hum Vaccin       Date:  2011-11-01

2.  Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection.

Authors:  Rafael Polidoro Alves Barbosa; Bruno Galvão Filho; Luara Isabela Dos Santos; Policarpo Ademar Sales Junior; Pedro Elias Marques; Rafaela Vaz Sousa Pereira; Denise Carmona Cara; Oscar Bruña-Romero; Maurício Martins Rodrigues; Ricardo Tostes Gazzinelli; Alexandre Vieira Machado
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

3.  Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi.

Authors:  Raquel Tayar Nogueira; Alanderson Rocha Nogueira; Mirian Claudia Souza Pereira; Maurício Martins Rodrigues; Patrícia Cristina da Costa Neves; Ricardo Galler; Myrna Cristina Bonaldo
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.